KR20200071097A - Parp 억제제 및 pd-1 축 결합 길항제의 조합 - Google Patents
Parp 억제제 및 pd-1 축 결합 길항제의 조합 Download PDFInfo
- Publication number
- KR20200071097A KR20200071097A KR1020207013511A KR20207013511A KR20200071097A KR 20200071097 A KR20200071097 A KR 20200071097A KR 1020207013511 A KR1020207013511 A KR 1020207013511A KR 20207013511 A KR20207013511 A KR 20207013511A KR 20200071097 A KR20200071097 A KR 20200071097A
- Authority
- KR
- South Korea
- Prior art keywords
- treatment
- cancer
- patient
- ddr
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N C[n]1ncnc1[C@H]([C@@H](c(cc1)ccc1F)Nc1c2c3cc(F)c1)C2=NNC3=O Chemical compound C[n]1ncnc1[C@H]([C@@H](c(cc1)ccc1F)Nc1c2c3cc(F)c1)C2=NNC3=O HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572024P | 2017-10-13 | 2017-10-13 | |
| US62/572,024 | 2017-10-13 | ||
| US201862697587P | 2018-07-13 | 2018-07-13 | |
| US62/697,587 | 2018-07-13 | ||
| PCT/US2018/055174 WO2019075032A1 (en) | 2017-10-13 | 2018-10-10 | COMBINATION OF A PARP INHIBITOR AND A PD-1 AXIS BINDING ANTAGONIST |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200071097A true KR20200071097A (ko) | 2020-06-18 |
Family
ID=64049735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207013511A Withdrawn KR20200071097A (ko) | 2017-10-13 | 2018-10-10 | Parp 억제제 및 pd-1 축 결합 길항제의 조합 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200254091A1 (enExample) |
| EP (1) | EP3694551A1 (enExample) |
| JP (1) | JP2020536887A (enExample) |
| KR (1) | KR20200071097A (enExample) |
| CN (1) | CN111225685A (enExample) |
| AU (1) | AU2018347331A1 (enExample) |
| BR (1) | BR112020006371A2 (enExample) |
| CA (1) | CA3078806A1 (enExample) |
| IL (1) | IL273994A (enExample) |
| MX (1) | MX2020003361A (enExample) |
| RU (1) | RU2020113246A (enExample) |
| TW (1) | TW201922288A (enExample) |
| WO (1) | WO2019075032A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190062515A (ko) * | 2016-10-06 | 2019-06-05 | 화이자 인코포레이티드 | 암의 치료를 위한 아벨루맙의 투약 용법 |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| TWI852940B (zh) * | 2018-09-04 | 2024-08-21 | 美商泰沙羅公司 | 治療癌症之方法 |
| CN113116881B (zh) * | 2019-12-31 | 2025-03-07 | 甫康（上海）健康科技有限责任公司 | 一种用于治疗肿瘤的药物组合及其应用 |
| JP2023524270A (ja) * | 2020-05-04 | 2023-06-09 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｐｄ－１アンタゴニスト、化学放射線療法およびｐａｒｐ阻害剤の組み合わせを用いた癌の治療方法 |
| WO2022200982A1 (en) * | 2021-03-24 | 2022-09-29 | Pfizer Inc. | Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer |
| TWI883565B (zh) | 2022-10-02 | 2025-05-11 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202425976A (zh) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202600137A (zh) | 2024-04-04 | 2026-01-01 | 美商輝瑞股份有限公司 | 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法 |
| WO2026078615A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
| WO2026078619A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| CN104478875B (zh) | 2008-08-06 | 2017-04-12 | 麦迪韦逊科技有限公司 | 聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂 |
| EP2531033A4 (en) | 2010-02-03 | 2013-07-31 | Biomarin Pharm Inc | POLY (ADP-RIBOSE) POLYMERASE (PARP) DIHYDROPYRIDOPHTHALAZINE HEMMER FOR USE IN THE TREATMENT OF PTEN-LACK ASSOCIATED DISEASES |
| KR101826652B1 (ko) | 2010-02-08 | 2018-02-07 | 메디베이션 테크놀로지즈, 인크. | 디히드로피리도프탈라지논 유도체의 합성 방법 |
| KR20190120458A (ko) | 2010-10-21 | 2019-10-23 | 메디베이션 테크놀로지즈 엘엘씨 | 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| CN105916846A (zh) | 2013-11-07 | 2016-08-31 | 麦迪韦逊科技有限公司 | 用于合成经保护的n-烷基三唑甲醛的三唑中间体 |
| PL3102605T3 (pl) * | 2014-02-04 | 2019-06-28 | Pfizer Inc. | Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu |
| EP3563870A1 (en) * | 2014-07-15 | 2019-11-06 | F. Hoffmann-La Roche AG | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| EA201790290A1 (ru) | 2014-07-31 | 2017-07-31 | Медивэйшн Текнолоджиз, Инк. | Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения |
| CN107206088A (zh) * | 2014-12-05 | 2017-09-26 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物 |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| RU2714233C2 (ru) * | 2015-02-26 | 2020-02-13 | Мерк Патент Гмбх | Ингибиторы pd-1 / pd-l1 для лечения рака |
| MX2017015937A (es) * | 2015-06-08 | 2018-12-11 | Genentech Inc | Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1. |
| SG11201803462PA (en) | 2015-10-26 | 2018-05-30 | Medivation Tech Llc | Treatment of small cell lung cancer with a parp inhibitor |
-
2018
- 2018-10-10 CA CA3078806A patent/CA3078806A1/en not_active Abandoned
- 2018-10-10 JP JP2020520007A patent/JP2020536887A/ja not_active Withdrawn
- 2018-10-10 US US16/754,485 patent/US20200254091A1/en not_active Abandoned
- 2018-10-10 EP EP18795891.3A patent/EP3694551A1/en not_active Withdrawn
- 2018-10-10 WO PCT/US2018/055174 patent/WO2019075032A1/en not_active Ceased
- 2018-10-10 BR BR112020006371-1A patent/BR112020006371A2/pt not_active IP Right Cessation
- 2018-10-10 RU RU2020113246A patent/RU2020113246A/ru unknown
- 2018-10-10 MX MX2020003361A patent/MX2020003361A/es unknown
- 2018-10-10 AU AU2018347331A patent/AU2018347331A1/en not_active Abandoned
- 2018-10-10 KR KR1020207013511A patent/KR20200071097A/ko not_active Withdrawn
- 2018-10-10 CN CN201880066544.4A patent/CN111225685A/zh active Pending
- 2018-10-12 TW TW107135947A patent/TW201922288A/zh unknown
-
2020
- 2020-04-16 IL IL273994A patent/IL273994A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018347331A1 (en) | 2020-04-09 |
| RU2020113246A (ru) | 2021-11-15 |
| BR112020006371A2 (pt) | 2020-09-29 |
| WO2019075032A1 (en) | 2019-04-18 |
| EP3694551A1 (en) | 2020-08-19 |
| JP2020536887A (ja) | 2020-12-17 |
| RU2020113246A3 (enExample) | 2021-11-15 |
| MX2020003361A (es) | 2020-07-29 |
| US20200254091A1 (en) | 2020-08-13 |
| CA3078806A1 (en) | 2019-04-18 |
| IL273994A (en) | 2020-05-31 |
| TW201922288A (zh) | 2019-06-16 |
| CN111225685A (zh) | 2020-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20200071097A (ko) | Parp 억제제 및 pd-1 축 결합 길항제의 조합 | |
| JP6591428B2 (ja) | 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ | |
| CA2787952C (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
| JP2020114840A (ja) | がんを治療するためのｐｄ−１／ｐｄ−ｌ１阻害剤 | |
| CA3165187A1 (en) | Methods for treatment of cancer with an anti-tigit antagonist antibody | |
| KR20130091745A (ko) | 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법 | |
| AU2014312130A1 (en) | Combination therapy for the treatment of glioblastoma | |
| KR20200101951A (ko) | 암을 치료하기 위한 방법 및 병용 요법 | |
| KR20130126576A (ko) | 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법 | |
| US20190216923A1 (en) | Methods and combination therapy to treat cancer | |
| US20200368205A1 (en) | Methods and combination therapy to treat cancer | |
| WO2019139583A1 (en) | Methods and combination therapy to treat cancer | |
| US20190211102A1 (en) | Methods and combination therapy to treat cancer | |
| HK40019847A (en) | Combination of a parp inhibitor and a pd-1 axis binding antagonist | |
| HK40013836A (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
| HK40031470A (en) | Methods and combination therapy to treat cancer | |
| HK40028739A (en) | Methods and combination therapy to treat cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20200512 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200512 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20210914 |
|
| WITB | Written withdrawal of application |